L-arginine supplementation increases mesangial cell injury and subsequent tissue fibrosis in experimental glomerulonephritis

Kidney International

Volumn 55, Issue 6, 1999, Pages 2264-2273

  Peters, Harm ^a   Border, Wayne A ^a   Noble, Nancy A ^a  

^a UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

Author keywords

Diabetic nephropathy; Fibrotic disease; Kidney; Nitric oxide; Rapidly progressive glomerulonephritis; TGF ; Tissue injury

Indexed keywords

ARGININE;

ALLERGIC GLOMERULONEPHRITIS; AMINO ACID METABOLISM; ANIMAL EXPERIMENT; ARTICLE; CYTOPATHOGENIC EFFECT; DISEASE COURSE; DISEASE SEVERITY; NONHUMAN; OXIDATION REDUCTION REACTION; PRIORITY JOURNAL; RAT;

EID: 0032989096     PISSN: 00852538     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1523-1755.1999.00462.x     Document Type: Article

References (46)

1. 1. Border WA, Noble NA: Transforming growth factor-β in tissue fibrosis. N Engl J Med 331:1286-1292, 1994
2. 2. Border WA, Noble NA: Evidence that TGF-β should be a therapeutic target in diabetic nephropathy. (editorial) Kidney Int 54:1390-1391, 1998
3. 3. Noble NA, Border WA: Angiotensin II in renal fibrosis: Should TGF-β rather than blood pressure be the therapeutic target? Semin Nephrol 17:455-466, 1997
4. 4. Narita I, Border WA, Ketteler M, Noble NA: Nitric oxide mediates immunologic injury to kidney mesangium in experimental glomerulonephritis. Lab Invest 72:17-24, 1995
5. 5. Ketteler M, Ikegaya N, Brees DK, Border WA, Noble NA: L-arginine metabolism in immune-mediated glomerulonephritis in the rat. Am J Kidney Dis 28:878-887, 1996
6. 6. Bogle RG, Baydoun AR, Pearson JD, Moncada S, Mann GE: L-Arginine transport is increased in macrophages generating nitric oxide. Biochem J 284:15-18, 1992
7. 7. Förstermann U, Closs EI, Pollock JS, Nakane M, Schwarz P, Gath I, Kleinert H: Nitric oxide synthase isozymes. Hypertension 23:1121-1131, 1994
8. 8. Waddington S, Cook HT, Reaveley D, Jansen A, Cattell V: L-arginine depletion inhibits glomerular nitric oxide synthesis and exacerbates rat nephrotoxic nephritis. Kidney Int 49:1090-1096, 1996
9. 9. Narita I, Border WA, Ketteler M, Ruoslahti E, Noble NA: L-arginine may mediate the therapeutic effects of low protein diets. Proc Natl Acad Sci USA 92:4552-4556, 1995
10. 10. Reyes AA, Pukerson ML, Karl I, Klahr S: Dietary supplementation with L-arginine ameliorates the progression of renal disease in rats with subtotal nephrectomy. Am J Kidney Dis 20:168-176, 1992
11. 11. Katoh T, Takahashi K, Klahr S, Reyes AA, Badr KF: Dietary supplementation with L-arginine ameliorates glomerular hypertension in rats with subtotal nephrectomy. J Am Soc Nephrol 4:1690-1694, 1994
12. 12. Reyes AA, Porras BH, Chasalow FI, Klahr S: L-arginine decreases the infiltration of the kidney by macrophages in obstructive nephropathy and puromycin-induced nephrosis. Kidney Int 45: 1346-1354, 1994
13. 13. Reyes AA, Karl IE, Yates J, Klahr S: Low plasma and renal tissue levels of L-arginine in rats with obstructive nephropathy. Kidney Int 45:782-787, 1994
14. 14. Morrissey JJ, Ishidoya S, McCracken R, Klahr S: Nitric oxide generation ameliorates the tubulointerstitial fibrosis of obstructive nephropathy. J Am Soc Nephrol 7:1-11, 1996
15. 15. Reyes AA, Karl IE, Kissane J, Klahr S: L-arginine administration prevents glomerular hyperfiltration and decreases proteinuria in diabetic rats. J Am Soc Nephrol 4:1039-1045, 1993
16. 16. Chen PY, St. John PL, Kirk KA, Abrahamson DR, Sanders PW: Hypertensive nephrosclerosis in the Dahl/Rapp rat: Initial sites of injury and effect of dietary L-arginine supplementation. Lab Invest 68:174-184, 1993
17. 17. De Nicola L, Thomson SC, Wead LM, Brown MR, Gabbai FB: Arginine feeding modifies cyclosporine nephrotoxicity in rats. J Clin Invest 92:1859-1865, 1993
18. 18. Ingram A, Parbtani A, Thai K, Ly H, Shankland SJ, Morrissey G, Scholey JW: Dietary supplementation with L-arginine limits cell proliferation in the remnant glomerulus. Kidney Int 48:1857-1865, 1995
19. 19. Ashab I, Peer G, Blum M, Wollman Y, Chernihovsky T, Hassner A, Schwartz D, Cabili S, Silverberg D, Iaina A: Oral administration of L-arginine and captopril in rats prevents chronic renal failure by nitric oxide production. Kidney Int 47:1515-1521, 1995
20. 20. Okuda S, Languino LR, Ruoslahti E, Border WA: Elevated expression of transforming growth factor-beta and proteoglycan production in experimental glomerulonephritis: Possible role in expansion of the mesangial extracellular matrix. J Clin Invest 86:453-462, 1990
21. 21. Nakane M, Pollock JS, Klinghofer V, Basha F, Marsden PA, Hokan A, Ogura T, Esumi H, Carter GW: Functional expression of three isoforms of human nitric oxide synthase in baculovirus-infected insect cells. Biochem Biophys Res Commun 206:511-517, 1995
22. 22. Fort P, Marty L, Piechaczyk M, Sabrouty SE, Dani C, Jeanteur PH, Blanchard JM: Various rat adult tissues express only one major mRNA species from the glyceraldehyde-3-phosphate-dehydrogenase multigenic family. Nucleic Acids Res 13:1431-1442, 1985
23. 23. Schuster R: Determination of amino acids in biological, pharmacological, plant and food samples by automated precolumn derivatization and high-performance liquid chromatography. J Chromatogr 431:271-284, 1988
24. 15N]nitrate in biological fluids. Anal Biochem 126:131-138, 1982
25. 25. Rennard SI, Berg R, Martin GR, Foidart JM, Robey PG: Enzyme-linked immunoassay (ELISA) for connective tissue components. Anal Biochem 104:205-214, 1980
26. 26. Castillo L, Ajami A, Branch S, Chapman TE, Yu YM, Burke JF, Young YR: Plasma arginine kinetics in adult man: Response to an arginine-free diet. Metabolism 43:114-122, 1994
27. 27. Peters H, Noble NA: Dietary L-arginine in renal disease. Semin Nephrol 6:567-575, 1996
28. 28. Noiri E, Peresleni T, Miller F, Goligorsky MS: In vivo targeting of inducible NO synthase with oligodeoxynucleotides protects rat kidney against ischemia. J Clin Invest 97:2377-2383, 1996
29. G-monometnyl-L-arginine. J Exp Med 179:651-660, 1994
30. 30. Cattell V, Smith J, Jansen A, Riveros-Moreno V, Moncada S: Localization of inducible nitric oxide synthase in acute renal allograft rejection in the rat. Transplantation 58:1399-1402, 1994
31. 31. Mulligan MS, Moncada S, Ward PA: Protective effects of inhibitors of nitric oxide synthase in immune complex-induced vasculitis. Br J Pharmacol 107:1159-1162, 1992
32. 32. Zhang F, Casey RM, Ross ME, Iadecola C: Aminoguanidine ameliorates and L-arginine worsens brain damage from intraluminal middle cerebral artery occlusion. Stroke 27:317-323, 1996
33. 33. Nozik ES, Huang Y-CT, Piantadosi CA: L-arginine enhances injury in the isolated rabbit lung during hyperoxia. Respir Physiol 100:63-74, 1995
34. 34. Neilly PJD, Gardiner KR, Rowlands BJ: Experimental colitis is ameliorated by inhibition of nitric oxide synthase activity. (letter) Gut 38:475, 1996
35. 35. Moncada S, Higgs A: The L-arginine-nitric oxide pathway. N Engl J Med 329:2002-2012, 1993
36. 36. Vouldoukis I, Riveros Moreno V, Dugas B, Quaaz F, Becherel P, Debre P, Moncada S, Mossalayi MD: The killing of Leishmania major by human macrophages is mediated by nitric oxide induced after ligation of the Fc epsilon RII/CD23 surface antigen. Proc Natl Acad Sci USA 92:7804-7808, 1995
37. 37. Nicholson S, Bonecini Almeida M, Lapa S, Nathan C, Xie QW, Mumford R, Weidner JR, Calaycay J, Boechat N: Inducible nitric oxide synthase in pulmonary alveolar macrophages from patients with tuberculosis. J Exp Med 183:2293-2302, 1996
38. 38. Sakurai H, Kohsaka H, Liu MF, Higashiyama H, Hirata Y, Kanno K, Saito I, Miyasaka N: Nitric oxide production and inducible nitric oxide synthase expression in inflammatory arthritidis. J Clin Invest 96:2357-2363, 1995
39. 39. Wheeler MA, Smith SD, Garcia Cardena G, Nathan CF, Weiss RM, Sessa WC: Bacterial infection induces nitric oxide synthase in human neutrophils. J Clin Invest 99:110-116, 1997
40. 40. Bukrinsky MI, Nottei HS, Schmidtmayerova H,Dubrovsky L, Flanagan CR, Mullins ME, Lipton SA, Gendelman HE: Regulation of nitric oxide synthase activity in human immunodeficiency virus type I (HIV-1)-infected monocytes: Implications for HIV-associated neurological disease. J Exp Med 181:732-745, 1995
41. 41. Adamson DC, Wildemann B, Sasaki M, Glass JD, McArthur JC, Christov VI, Dawson TM, Dawson VL: Immunologic NO synthase: Elevation in severe AIDS dementia and induction by HIV-1 gp41. Science 274:1917-1921, 1996
42. 42. Xiao L, Eneroth PH, Qureshi GA: Nitric oxide synthase pathway may mediate human natural killer cell cytotoxicity. Scand J Immunol 42:505-511, 1995
43. 43. Beckman JS, Koppenol WH: Nitric oxide, superoxide, and peroxynitrite: The good, the bad, and ugly. Am J Physiol 271:C1424-C1437, 1996
44. 44. Kashem A, Endoh M, Yano N, Yamauchi F, Nomoto Y, Sakai H: Expression of inducible-NOS in human glomerulonephritis: The possible source is infiltrating monocytes/macrophages. Kidney Int 50:392-399, 1996
45. 45. MacMillan-Crow LA, Crow JP, Kerby JD, Beckman JS, Thompson JA: Nitration and inactivation of manganese superoxide dismutase in chronic rejection of human renal allografts. Proc Natl Acad Sci USA 93:11853-11858, 1996
46. 46. Klahr S, Morrissey J: Renal disease: The two faces of nitric oxide. Lab Invest 72:1-3, 1995